BL

BRIAN LOOSER

Not currently registered

At a glance

Status
Inactive
last filed Apr 2025
Clients
0
past 12 months
Filings
0
0 agencies · past 12 months
Activity
filings by quarter

Background

Career
Irvine, CA
2024 - present
Government experience
Pol. Ad.
Sen. Bill Cassidy, LA) LD (Rep. John Shimkus, IL-15) Sr Policy Advisor (Sen. Mark Kirk, IL) LA (Rep. Judy Biggert, IL-13) Leg. Corr./LA (Rep. Michele Bachmann, MN-06) Staff Asst./Leg. Corr.(Rep. Dennis Hastert, IL-14
Disclosed on LD-2 filings

Specific issues

CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Medicare/Medicaid · 2025 Q1
Corporate Tax Reform Proposals
Taxation/Internal Revenue Code · 2025 Q1
Ensuring Patient Access to Critical Breakthrough Products (H.R.1691 S.5349) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
Health Issues · 2025 Q1
Veterans Access to MedTech
Veterans · 2025 Q1
CMS Coverage Policies For Medical Devices Implementation of PL 114-255, 21st Century Cures Act CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Health Equity Issues Coverage with Evidence Development
Medicare/Medicaid · 2024 Q4
Implementation of PL 114-255, 21st Century Cures Act Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5439) Transitional Coverage for Emerging Technologies (TCET) guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Health Equity Issues (Diversity in Clinical Trials) H.R.6000 Cures 2.0 Act (includes CURES 2.1 proposal) Shortage Reporting Coverage with Evidence Development
Health Issues · 2024 Q4

Clients

No client work disclosed in the past 12 months.

Past clients1
2024-2025 · 5 filings
$██,███ / qtrUnlock

Filings · past 12 months

Nothing filed in the past 12 months.

Older filings5
2025 Q1
EDWARDS LIFESCIENCES LLC
Q1lda.gov →
2024 Q4
EDWARDS LIFESCIENCES LLC
Q4lda.gov →
2024 Q3
EDWARDS LIFESCIENCES LLC
Q3lda.gov →
2024 Q2
EDWARDS LIFESCIENCES LLC
Q2lda.gov →
2024 Q1
EDWARDS LIFESCIENCES LLC
Q1lda.gov →
Full record on lda.gov